Japan to extend foreign investment controls to Avigan suppliers: Yomiuri

FILE PHOTO: Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm's headquarters in Tokyo October 22, 2014. REUTERS/Issei Kato/File Photo

TOKYO (Reuters) - The Japanese government plans to implement strict controls on foreign investment in companies involved in the coronavirus treatment Avigan, the Yomiuri newspaper reported.

The move would be an extension of revised rules on foreign ownership in companies deemed critical to national security. The Ministry of Finance released a list of 518 such companies on Friday.

Japan's Fujifilm Holdings Corp 4901.T is working with domestic suppliers to ramp up production of its anti-flu drug Avigan that is being tested as a treatment for COVID-19.

Chemical makers Denka Co 4061.T and Kaneka Corp 4118.T are among Avigan raw materials suppliers that would be subject to the revised ownership rules, Yomiuri said.

Reporting by Rocky Swift; Editing by Kim COghill